AKR1B10 and familial pancreatic carcinoma: Previous study had demonstrated that OA was the most potent AKR1B10 competitive inhibitor, which was used in pancreatic cancer to inhibit the AKR1B10 activity, and thereby suppressed cell growth in vitro and in vivo24,25.